Ionic milieu controls the compartment-specific activation of pro-opiomelanocortin processing in AtT-20 cells.
Newly synthesized prohormones and their processing enzymes transit through the same compartments before being packaged into regulated secretory granules. Despite this coordinated intracellular transport, prohormone processing does not occur until late in the secretory pathway. In the mouse pituitary AtT-20 cell line, conversion of pro-opiomelanocortin (POMC) to mature adrenocorticotropic hormone involves the prohormone convertase PC1. The mechanism by which this proteolytic processing is restricted to late secretory compartments is unknown; PC1 activity could be regulated by compartment-specific activators/inhibitors, or through changes in the ionic milieu that influence its activity. By arresting transport in a semi-intact cell system, we have addressed whether metabolically labeled POMC trapped in early secretory compartments can be induced to undergo conversion if the ionic milieu in these compartments is experimentally manipulated. Prolonged incubation of labeled POMC trapped in the endoplasmic reticulum or Golgi/trans-Golgi network did not result in processing, thereby supporting the theory that processing is normally a post-Golgi/trans-Golgi network event. However, acidification of these compartments allowed effective processing of POMC to the intermediate and mature forms. The observed processing increased sharply at a pH below 6.0 and required millimolar calcium, regardless of the compartment in which labeled POMC resided. These conditions also resulted in the coordinate conversion of PC1 from the 84/87 kDa into the 74-kDa and 66-kDa forms. We propose that POMC processing is predominantly restricted to acidifying secretory granules, and that a change in pH within these granules is both necessary and sufficient to activate POMC processing.
Schmidt
W K
WK
University of California at Berkeley, Department of Molecular and Cell Biology 94720-3200, USA.
Moore
H P
HP
D000324:Adrenocorticotropic Hormone / Q000096:biosynthesis; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016282:Aspartic Acid Endopeptidases / Q000096:biosynthesis / Q000378:metabolism; D001692:Biological Transport / Q000187:drug effects; D020126:Brefeldin A; D002118:Calcium / Q000502:physiology; D002451:Cell Compartmentation; D002460:Cell Line; D003517:Cyclopentanes / Q000494:pharmacology; D003594:Cytoplasmic Granules / Q000378:metabolism*; D004721:Endoplasmic Reticulum / Q000378:metabolism; D005033:Ethylmaleimide / Q000494:pharmacology; D006056:Golgi Apparatus / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D018942:Macrolides; D051379:Mice; D010903:Pituitary Gland, Anterior / Q000166:cytology / Q000201:enzymology / Q000378:metabolism*; D011333:Pro-Opiomelanocortin / Q000378:metabolism*; D045664:Proprotein Convertase 1; D043484:Proprotein Convertases; D011499:Protein Processing, Post-Translational / Q000502:physiology*; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D003517:Cyclopentanes; D018942:Macrolides; D020126:Brefeldin A; D011333:Pro-Opiomelanocortin; C040929:bafilomycin A1; D000324:Adrenocorticotropic Hormone; D043484:Proprotein Convertases; C473656:Pcsk1 protein, mouse; D045664:Proprotein Convertase 1; D016282:Aspartic Acid Endopeptidases; D006180:Proton-Translocating ATPases; D005033:Ethylmaleimide; D002118:Calcium